Amphastar Pharmaceuticals reports after the bell today with the Street decisively negative and short interest near its highest level of the year.
The short-side positioning is a genuine story here. Bears hold 9.4% of the free float — up nearly 20% over the past month — making this one of the more crowded short books in the pharmaceuticals space. Despite that build, the borrow market remains loose: availability runs at 521%, meaning roughly five shares are available to borrow for every one already lent out, and the cost to borrow is a trivial 0.5%. That combination — heavy short positioning, but no friction in the lending market — suggests shorts face no mechanical pressure ahead of the print. Options traders are leaning the opposite direction. The put/call ratio has collapsed to 0.12, well below the 20-day average of 0.22 and closer to the annual low of 0.03 than the annual high of 0.53. That tilt toward calls signals some contingent of traders is positioned for an upside surprise, even as the short book grows.
The analyst community has moved decisively against the stock in recent months. B of A Securities downgraded to Underperform in late June and cut its target to $20, the most recent in a string of actions that included downgrades from Wells Fargo and Needham and target reductions from Barclays and Piper Sandler. The consensus has settled at Hold, with a mean target of $22 — roughly 11% above the current $19.81 close, though that gap has narrowed sharply as targets have been slashed from the low-$30s range seen in late 2025. The bear case centres on Baqsimi underperformance, pricing headwinds in generics, and a pipeline that does not deliver meaningful new product approvals until 2027. The theoretical bull case rests on valuation: the stock trades at roughly 7x earnings and 6x EV/EBITDA, inexpensive multiples that could attract buyers if the company shows any stabilisation in top-line trends. EPS momentum scores rank in the bottom quintile of the universe, however, suggesting analysts remain sceptical that a positive revision cycle is near.
One ownership detail stands out. Applied Physics & Chemistry Laboratories — a founding-affiliated entity — holds 15.5% of shares, and CEO Jack Zhang controls another 6%. Both positions were static in the most recent filings. That concentrated insider base limits the float and amplifies any post-earnings move in either direction. The most recent comparable print, in June, saw the stock fall 2.1% on the day before recovering 2.9% over the following five sessions — a muted reaction that may not repeat given the degree to which sentiment has deteriorated since.
Today's print is therefore less a test of whether Amphastar can grow and more a question of whether the company can offer any credible path to revenue stabilisation before the 2027 pipeline window — enough to challenge the Wall Street consensus that has spent four months moving in one direction.
See the live data behind this article on ORTEX.
Open AMPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
